Yuemei Wang

478 total citations
13 papers, 85 citations indexed

About

Yuemei Wang is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yuemei Wang has authored 13 papers receiving a total of 85 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Reproductive Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yuemei Wang's work include Ovarian cancer diagnosis and treatment (6 papers), PARP inhibition in cancer therapy (3 papers) and Advanced Breast Cancer Therapies (2 papers). Yuemei Wang is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), PARP inhibition in cancer therapy (3 papers) and Advanced Breast Cancer Therapies (2 papers). Yuemei Wang collaborates with scholars based in United States, Canada and Italy. Yuemei Wang's co-authors include Kathleen N. Moore, Gottfried E. Konecny, Toon Van Gorp, Michael Method, Domenica Lorusso, Lucy Gilbert, Ursula A. Matulonis, Susana Banerjee, Diane Provencher and Anna Berkenblit and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Ophthalmology and Gynecologic Oncology.

In The Last Decade

Yuemei Wang

11 papers receiving 84 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuemei Wang United States	4	59	51	21	13	12	13	85
Simona Ruisi Italy	2	36 0.6×	36 0.7×	10 0.5×	4 0.3×	20 1.7×	2	71
Sarah Farooq United States	6	32 0.5×	64 1.3×	8 0.4×	11 0.8×	5 0.4×	10	84
Angela Jain United States	4	35 0.6×	23 0.5×	9 0.4×	15 1.2×	5 0.4×	14	68
P. Hoskins Canada	4	51 0.9×	35 0.7×	20 1.0×	8 0.6×	36 3.0×	4	83
Ana Santaballa Bertrán Spain	5	40 0.7×	30 0.6×	13 0.6×	9 0.7×	9 0.8×	11	81
M.P. Barretina Ginesta Spain	4	77 1.3×	46 0.9×	23 1.1×	85 6.5×	5 0.4×	19	123
Reena Merard United Kingdom	6	38 0.6×	17 0.3×	7 0.3×	21 1.6×	12 1.0×	7	80
E. Salinas United States	6	51 0.9×	23 0.5×	22 1.0×	35 2.7×	4 0.3×	22	105
Dennis Mauricio United States	3	13 0.2×	36 0.7×	5 0.2×	33 2.5×	23 1.9×	6	92
Maria Natale Italy	6	14 0.2×	20 0.4×	26 1.2×	26 2.0×	7 0.6×	17	89

Countries citing papers authored by Yuemei Wang

Since Specialization

Citations

This map shows the geographic impact of Yuemei Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuemei Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuemei Wang more than expected).

Fields of papers citing papers by Yuemei Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuemei Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuemei Wang. The network helps show where Yuemei Wang may publish in the future.

Co-authorship network of co-authors of Yuemei Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Yuemei Wang. A scholar is included among the top collaborators of Yuemei Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuemei Wang. Yuemei Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Wang, Yuemei, et al.. (2025). Ultrasonic-assisted extraction and biological activities of traditional Chinese/Mongolian medical herb Artemisia ordosica Krasch. using natural deep eutectic solvents. Microchemical Journal. 213. 113669–113669. 1 indexed citations

Wang, Yuemei, et al.. (2025). Influence of natural deep eutectic solvents on Artemisia ordosica Krasch. extraction: compositional characterization, mechanism and biological activities. Microchemical Journal. 216. 114715–114715.

Tolcher, Anthony W., Tanya B. Dorff, Sumiko Okubo, et al.. (2025). Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 43(16_suppl).

Coleman, Robert L., Domenica Lorusso, Ana Oaknin, et al.. (2024). Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. International Journal of Gynecological Cancer. 34(8). 1119–1125. 11 indexed citations

Richardson, Debra L., Kathleen N. Moore, Ignace Vergote, et al.. (2024). Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology. 185. 186–193. 19 indexed citations

Lorusso, Domenica, Ana Oaknin, Amit M. Oza, et al.. (2024). Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary. Gynecologic Oncology. 191. 249–258. 8 indexed citations

Tu, Ya‐Ping, H. Maxime Lagraauw, Michael Method, et al.. (2024). Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. British Journal of Clinical Pharmacology. 91(1). 220–231. 1 indexed citations

Bello, Diana, Toon Van Gorp, Gottfried E. Konecny, et al.. (2024). Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.. Journal of Clinical Oncology. 42(16_suppl). 5580–5580. 1 indexed citations

Tu, Ya‐Ping, et al.. (2024). Assessment of mirvetuximab soravtansine immunogenicity in patients with folate receptor alpha-positive ovarian cancer. Bioanalysis. 16(21-22). 1101–1113. 1 indexed citations

10.

Gorp, Toon Van, Renaud Sabatier, Gottfried E. Konecny, et al.. (2023). #1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial. A29.2–A30. 2 indexed citations

11.

Moore, Kathleen N., Antoine Angelergues, Gottfried E. Konecny, et al.. (2023). Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.. Journal of Clinical Oncology. 41(17_suppl). LBA5507–LBA5507. 37 indexed citations

12.

Moore, Kathleen N., Dominique Berton, Gottfried E. Konecny, et al.. (2023). #1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial. A30.1–A30. 1 indexed citations

13.

Ta, Christopher N., Michael B. Raizman, Robert D. Gross, et al.. (2020). A Prospective, Randomized Trial of Povidone-Iodine 0.6% and Dexamethasone 0.1% Ophthalmic Suspension for Acute Bacterial Conjunctivitis. American Journal of Ophthalmology. 215. 56–65. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact